Aventis Pasteur, Inc. v. Skevofilax

914 A.2d 113, 396 Md. 405, 2007 Md. LEXIS 8
CourtCourt of Appeals of Maryland
DecidedJanuary 8, 2007
Docket15, Sept. Term, 2006
StatusPublished
Cited by76 cases

This text of 914 A.2d 113 (Aventis Pasteur, Inc. v. Skevofilax) is published on Counsel Stack Legal Research, covering Court of Appeals of Maryland primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Aventis Pasteur, Inc. v. Skevofilax, 914 A.2d 113, 396 Md. 405, 2007 Md. LEXIS 8 (Md. 2007).

Opinion

HARRELL, J.

On 14 April 2003, Helen and John Skevofílax (Respondents here), individually and as next friends of their eight-year-old son, Michael, filed suit in the Circuit Court for Baltimore City seeking damages from Defendants (Petitioners here), several corporations engaged in the manufacture of pediatric vaccines and the ingredients incorporated in the vaccines. 1 The Plaintiffs-Respondents claimed that Michael’s autism spectrum disorder was caused by thimerosal, a mercury-containing preser *409 vative used in pediatric vaccines administered to Michael as an infant. The disposition of the complaint on preliminary motions is what brings this case to us. On 21 December 2004, the Circuit Court denied Respondents’ motion for dismissal of the complaint without prejudice, and granted summary judgment in Petitioners’ favor. The court, having extended discovery three times by way of amended scheduling orders, determined that summary judgment was appropriate in light of Respondents’ “conceded inability to produce an expert witness on the area of specific causation in connection with this proceeding.”

Respondents noted a timely appeal, arguing that the trial court abused its discretion in denying their motion to dismiss without prejudice pursuant to Maryland Rule 2-506(b). 2 The Court of Special Appeals, in a reported opinion, 3 agreed with *410 the Skevofílaxes and reversed. The intermediate appellate court reasoned that the need to protect Michael’s rights as a minor warranted a voluntary dismissal, in lieu of the summary judgment entered in Petitioners’ favor.

For reasons we shall explain, we reverse the judgment of the Court of Special Appeals. It was neither an abuse of discretion by the Circuit Court to deny Respondents’ motion to dismiss nor error of law to enter summary judgment in favor of Petitioners.

BACKGROUND

Respondents’ complaint in the Circuit Court alleged that toxic levels of mercury in the thimerosal contained in vaccinations, administered to Michael as a baby, caused his autism. 4 This lawsuit thus became one of many thimerosal vaccine cases maintained throughout the country.

On 30 September 2003 Judge Stuart R. Berger of the Circuit Court for Baltimore City was assigned specially to preside over the case. 5 The parties met on 13 November 2003 in order to discuss a scheduling order for discovery, preliminary motions, oppositions and replies, pre-trial conferences, and the trial itself. The court issued, on 18 November 2003, a Scheduling Order requiring completion of all discovery, including depositions and resolution of any fact discovery disputes, no later than 30 July 2004. The Order further directed the identification of Respondents’ expert witnesses on or before 1 September 2004 and identification of Petitioners’ experts by *411 no later than 1 November 2004. The experts were required to be available for deposition no later than by 30 September and 30 November 2004, respectively. The Order also called for completion of all discovery of experts, including depositions, no later than 15 December 2004, required all dispositive motions to be filed no later than 15 February 2005, and directed that the parties attend a pre-trial conference on 4 April 2005. Trial was set for 2 May 2005.

Discovery began with the depositions of Mr. and Mrs. Skevofilax, and the scheduling of several other depositions to be taken at a later date. By letter dated 24 May 2004, however, Respondents’ counsel expressed doubt to the Circuit Court that the 30 July 2004 deadline for completion of fact discovery could be met. According to Respondents, GlaxoSmithKline recently was added as a defendant by the Second Amended Complaint filed on 24 May 2004, and Wyeth had served Respondents’ counsel with approximately 20,000 documents in response to Respondents’ discovery requests. The Skevofilaxes accordingly filed a Motion to Modify the Scheduling Order on 15 June 2004. Following a hearing, the court ordered on 13 July 2004 (the Amended Scheduling Order) that the following changes be made in the Scheduling Order: (1) the date for completion of fact discovery was extended from 30 July 2004 to 15 December 2004; (2) the deadline for designation of Respondent’s expert witnesses was pushed-back two weeks to 15 September 2004, and the time for deposing those experts was likewise moved to 15 October 2004; (3) the date for identification of Petitioner’s witnesses was moved back one week to 8 November 2004; and, (4) the deadline for deposing them was changed to 7 December 2004 from 30 November 2004. Judge Berger refused, however, to grant Respondents’ request to move the trial date to 19 September 2005 because time constraints imposed by operation of the Circuit Court’s docket rotation system mitigated against such a delay. 6

*412 Respondents filed a Motion to Modify Amended Scheduling Order on 2 August 2004, citing the “extensive document production, numerous depositions of fact witnesses and corporate designees, and the appearance of [GlaxoSmithKline] ....” 7 After another hearing, the Circuit Court, on 2 September 2004, again extended discovery (Second Amended Scheduling Order). The time for designation of Respondents’ experts was extended another three weeks to 8 October 2004, and those experts were to be available for deposition by no later than 5 November 2004. The deadline for identification of Petitioners’ experts was changed to 29 November 2004, and they were to be available for deposition on or before 20 December 2004. The deadline for completion of all discovery as to proposed expert witnesses was extended five days to 20 December 2004.

Respondents designated four expert witnesses as to liability and four experts as to damages on 7 October 2004. One, James Jeffrey Bradstreet, M.D., was designated to testify to specific causation, i.e., “that significant amounts of mercury to which the minor plaintiff was exposed, including bolus doses received as a result of vaccination, was a substantial factor in causing [Michael’s] current injuries and symptoms,” and further, “that the exposure to toxic levels of mercury within the vaccines [was] a substantial contributing factor to the minor Plaintiffs ultimate injuries and symptoms.” Dr. Bradstreet was the sole expert named by Respondents on the question of specific causation. 8

*413 On 26 October 2004, Respondents notified Petitioners, by letter, that “due to unforeseen circumstances [genomic profiling] test results critical to [Dr.] Bradstreet’s opinions” would be delayed up to sixty days. 9 The relevant genomic susceptibility tests assertedly needed for Dr. Bradstreet’s expert medical opinion were being performed by a laboratory at the University of Arkansas. An affidavit completed by Dr.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Maryland Indoor Play v. Snowden Investment
Court of Appeals of Maryland, 2025
In the Matter of HRVC Lt'd P'ship
Court of Special Appeals of Maryland, 2025
Bhargava v. Prince George's Cnty. Planning Bd.
Court of Special Appeals of Maryland, 2025
Lins v. United States
D. Maryland, 2024
Green v. State
Court of Special Appeals of Maryland, 2023
HBC US Propco v. Fed. Realty Inv. Trust
Court of Special Appeals of Maryland, 2023
Andrews v. O'Sullivan
Court of Special Appeals of Maryland, 2022
Green v. Obsu
D. Maryland, 2022
Neal v. United States
D. Maryland, 2022
Alexander v. Alexander
Court of Special Appeals of Maryland, 2021
Williams v. State
Court of Special Appeals of Maryland, 2021
Thornton Mellon v. Dennis Exempt Trust
250 A.3d 295 (Court of Special Appeals of Maryland, 2021)
Ademiluyi v. Egbuono
466 Md. 80 (Court of Appeals of Maryland, 2019)
Heffington v. Moser
192 A.3d 900 (Court of Special Appeals of Maryland, 2018)
In the Matter of the Hon. Mary C. Reese
Court of Appeals of Maryland, 2018
Sugarman v. Liles
190 A.3d 344 (Court of Appeals of Maryland, 2018)
Lamalfa v. Hearn
178 A.3d 501 (Court of Appeals of Maryland, 2018)

Cite This Page — Counsel Stack

Bluebook (online)
914 A.2d 113, 396 Md. 405, 2007 Md. LEXIS 8, Counsel Stack Legal Research, https://law.counselstack.com/opinion/aventis-pasteur-inc-v-skevofilax-md-2007.